Please login to the form below
Spark Therapeutics
This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
Also in the running is SPK-8011 from Spark Therapeutics – although this contender suffered a setback in 2018 after two patients treated with the therapy developed immune reactions.
Latest news
-
Roche pays $1.15bn for Sarepta’s Duchenne gene therapy
Pens another gene therapy deal following takeover of Spark Therapeutics. Fresh from its drawn-out takeover of Spark Therapeutics, Roche has signed another gene therapy deal, licensing Sarepta’s Duchenne muscular
-
Roche to close $4.3bn Spark deal after FTC clearance
Comes on the heels of CMA green light. After ten long months of waiting, Roche can finally go-ahead with its $4.3bn takeover of gene therapy specialist Spark Therapeutics, following ... with and into Spark without a vote or meeting of Spark’s
-
UK’s CMA clears Roche’s $4.3bn takeover of Spark
Roche first announced deal in February. Its a happy day for Roche, as it clears one of the hurdles in the way of its $4.3 acquisition of Spark Therapeutics, after ... Adding Spark’s gene therapies SPK-8011 and earlier-stage follow-up SPK-8061 for
-
Sangamo steps up BioMarin chase with haemophilia gene therapy data
data to come in on all the near-term candidates – which also includes Spark Therapeutics’ SPK-8011 – to see which has the best clinical profile. ... Spark suffered a setback last year after two patients treated with SPK-8011 developed immune
-
Astellas makes gene therapy a core focus with $3bn Audentes buy
Deal includes a late-stage candidate for a rare disease. Astellas has made a foray into gene therapy with the acquisition of Audentes Therapeutics for $3bn, adding a late-stage candidate ... Spark Therapeutics for $4.3bn.
More from news
Approximately 17 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
Pharma’s return? Positive data on one of the combinations or approval of aducanumab could spark renewed interest in treating Alzheimer’s. ... Such a shift has recently happened in the gene therapy space, which was a backwater pursued largely by
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close to that $1m mark. ... Fellow US gene therapy company Spark was acquired by Roche for $4.3bn in
-
Drug launches to watch in 2019
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Unlike fellow Boston, MA-based gene therapy company Spark
-
The European Medicines Agency: PRIME’d for access?
sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when
-
Bluebird Bio: on the cusp of a gene therapy revolution
drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... of a more stable adeno-associated virus (AAV) – which now forms the basis of Spark Therapeutics’ drugs and,
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Industry appointments
Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AZ strengthens Daiichi Sankyo partnership with new ADC deal
- New study identifies drugs that are safe to use in COVID-19 treatment
- AbbVie, Amgen and Takeda team up for joint COVID-19 trial
- Novavax reports promising phase 1 results for coronavirus vaccine
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Porterhouse Medical Group joins imc group
- Biogen pays Denali $1bn upfront for Parkinson’s disease programme
- Tecentriq combo fails in advanced triple negative breast cancer
- Bristol-Myers Squibb’s revenues rise on Celgene acquisition
- Socially distanced strategising
- Artificial Intelligence in Digital Therapeutics
PMHub
Windrose Consulting Group
Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
